ETON
Eton Pharmaceuticals, Inc.
ETON has the edge over OSCR overall, supported by lower modeled downside and stronger fundamentals.
OSCR
Oscar Health, Inc.
OSCR offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
ETON Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Healthy |
ETON's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ETON PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 24x | $61.45 | — |
| Current | 41x | $61.45 | — |
| Cheap | 79x | $121 | +97% |
| Fair | 85x | $130 | +111% |
| Expensive | 149x | $227 | +269% |
Historical ranges are pointers, not guarantees.
ETON's PE is 41x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ETON in the historical PE scenario, which offers more potential upside but is not a forecast.
ETON Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for ETON, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ETON Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.51 | +65% |
| Q3 2026 | $1.52 | +$1.77 |
| Q2 2026 | $0.39 | +$0.55 |
| Q1 2026 | -$0.06 | +$0.12 |
| Q4 2025 | -$0.17 | -$0.02 |
| Q3 2025 | -$0.25 | -$0.03 |
| Q2 2025 | -$0.16 | +$0.10 |
| Q1 2025 | -$0.18 | -550% |
| Q4 2022 | -$0.35 | -$0.27 |
ETON has returned to profit: it earned $1.52 per share over the past year, after losing money the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ETON Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $57.9M | +158% |
| Q2 2026 | $37.6M | +99% |
| Q1 2026 | $24.3M | +40% |
| Q4 2025 | $21.3M | +83% |
| Q3 2025 | $22.5M | +118% |
| Q2 2025 | $18.9M | +109% |
| Q1 2025 | $17.3M | +117% |
| Q4 2024 | $11.6M | +59% |
ETON has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | +46 points |
| Q2 2026 | 34% | +42 points |
| Q1 2026 | 10% | +13 points |
| Q4 2025 | 12% | +6.2 points |
| Q3 2025 | -6.1% | -11 points |
| Q2 2025 | -7.8% | +25 points |
| Q1 2025 | -2.7% | +7.3 points |
| Q4 2024 | 5.4% | +33 points |
ETON has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ETON Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $35.2M | +200% |
| Q2 2026 | $7.3M | -8.8% |
| Q1 2026 | $7.3M | +251% |
| Q4 2025 | -$11.6M | -$10.8M |
| Q3 2025 | $11.7M | +298% |
| Q2 2025 | $8M | +534% |
| Q1 2025 | $2.1M | +$4.6M |
| Q4 2024 | -$777K | -301% |
ETON generated $38M in free cash flow over the past year, up 82% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ETON on cash flow, with more consistent year-over-year improvement.
ETON Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +477K shares |
| 1 year | +24% | +6.4M shares |
| 3 years | +32% | +8.1M shares |
| 5 years | +58% | +12.2M shares |
ETON has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ETON Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | -9.6x | Net Cash |
| Q2 2025 | 2.6x | Moderate |
| Q1 2024 | -7.9x | Net Cash |
| Q3 2023 | -7.1x | Net Cash |
ETON has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ETON on leverage, with a lower net debt burden relative to earnings.
ETON Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.9 | Neutral |
| Stochastic | 58.6 | Neutral |
ETON's weekly RSI is 70 (neutral) and its Stochastic is 59 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ETON PE vs Healthcare Sector
| Metric | ETON | Sector median | Relative |
|---|---|---|---|
| PE | 41x | 26x | 57% above |
| PE % | 4 | 29 | 25 pts below |
ETON is trading at 41x earnings, a 57% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ETON on valuation relative to its sector.
ETON Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $54.8 | 12% above |
| 20 week MA | $52.1 | 18% above |
| 50 week MA | $34.3 | 79% above |
| 100 week MA | $25.2 | 144% above |
| 200 week MA | $14.9 | 313% above |
ETON is in an uptrend: it's above all five of its weekly moving averages, and 313% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
ETON Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.02 | $8.78 | +25% |
| 2021 | $8.78 | $4.26 | -51% |
| 2022 | $4.26 | $3.05 | -28% |
| 2023 | $3.05 | $4.38 | +44% |
| 2024 | $4.38 | $13.1 | +198% |
| 2025 | $13.1 | $16.8 | +29% |
| 2026 YTD | $16.8 | $61.5 | +265% |
ETON has the edge over OSCR on returns for 2026, with the stronger performance.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.